Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03287830 · ClinicalTrials.gov registry record · NA
Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 2,105
- Enrollment target
NCT03287830: Completed NA study, sponsored by Columbia University.
NCT03287830 is a NA study that has completed, run by Columbia University. The registered enrollment target is 2,105 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03287830, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,105 participants
- Enrollment target
Study Summary
This multi-site study assesses the impact of text message reminders on the receipt of the second dose of influenza vaccine, and takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) network.
Primary Outcome
Receipt of second dose influenza vaccine by the end of flu season, which is April 30 each year
Interventions
- BEHAVIORAL Text message influenza vaccine reminders
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,105 participants |
| Start Date | 2017-10-06 |
| Est. Completion | 2019-04-30 |
| Phase | NA |
What the finished NCT03287830 record still lists
NCT03287830 is an interventional study that assigns participants to a tested intervention. Its 2,105 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 1 intervention - of which Text message influenza vaccine reminders is the first listed.
NCT03287830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03287830 about?
NCT03287830 is a clinical study titled "Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine". This multi-site study assesses the impact of text message reminders on the receipt of the second dose of influenza vaccine, and takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) network.
What is the current status of trial NCT03287830?
This trial is currently completed. It is a NA study. The enrollment target is 2,105 participants. The study started on 2017-10-06. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT03287830?
The interventions under investigation include: Text message influenza vaccine reminders (BEHAVIORAL).
Who is sponsoring clinical trial NCT03287830?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03287830's enrollment target sits among peer trials
2,105 49th of 2000 higher than 1,952 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI